216974-75-3
216974-75-3
Chemical Structure
Bevacizumab
Synonym(s): Anti-Human VEGF, Humanized Antibody
- CAS. Nr.: 216974-75-3
- Formula:N/A
- Molecular Weight:(146.56 kDa)
SMILES: [Bevacizumab]
Biological Activity: Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bevacizumab | 98.90% | Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bevacizumab (Anti-VEGFA) | 99.07% | Bevacizumab (Anti-VEGFA) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab (Anti-VEGFA) blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab (Anti-VEGFA) possesses immunomodulatory properties. Bevacizumab (Anti-VEGFA) can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
